The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
This new facility strengthens Latin America as a collaborative hub
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Subscribe To Our Newsletter & Stay Updated
